MIE UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160138097 | METHOD FOR DETECTING METHYLATED DNA - Provided is a rapid and simple method of detecting methylated DNA. The method of detecting methylated DNA includes the following steps of: (1) treating sample DNA with a hydrogen sulfite; (2) amplifying the sample DNA treated with the hydrogen sulfite by PCR; and (3) subjecting the resultant PCR amplification product to ion-exchange chromatography. | 05-19-2016 |
20160130586 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. | 05-12-2016 |
20140322760 | METHOD FOR PRODUCING VIRUS VECTOR FOR GENE TRANSFER - The present invention discloses a cell system, as a host cell to be infected with an F gene-deficient virus, which can constitutively and stably express the F protein, and a method for producing an F gene-deficient virus by utilizing the cell. A non-proliferative human parainfluenza type 2 virus vector is produced by co-culturing an F gene-deficient human parainfluenza type 2 virus with a Vero cell having the F gene of human parainfluenza type 2 virus in such a manner that the F gene is non-inducibly expressed, and isolating viral particles from a culture supernatant. | 10-30-2014 |
20140322344 | VACCINE PREPARATION FOR CANCER TREATMENT - A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent. | 10-30-2014 |
20140288151 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. | 09-25-2014 |
20140120124 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 05-01-2014 |
20130273436 | LITHIUM ION SECONDARY BATTERY - A lithium ion secondary battery is provided, including: a positive electrode and a negative electrode into which, and from which, lithium ions can be introduced and be discharged reversibly, and an electrolyte membrane placed therebetween, wherein the electrolyte membrane is obtained using an electrolyte made by blending (A) a polyanion type lithium salt, (B) a boron compound, and (C) an organic solvent. | 10-17-2013 |
20130217754 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1. | 08-22-2013 |
20130115199 | T-CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 05-09-2013 |
20130078635 | RAPID METHOD FOR IDENTIFYING DRUG-RESISTANT GENE USING ARTIFICIAL CHROMOSOME OF PLASMODIUM, AND METHOD FOR PREPARING RECOMBINANT PLASMODIUM - The present invention relates to a rapid method for identifying a drug-resistant gene using an artificial chromosome of a protozoa. Specifically, it relates to a method for screening for a drug-resistant gene, which involves preparing a recombinant | 03-28-2013 |
20120315547 | SOLID ELECTROLYTE COMPOSITION, SOLID ELECTROLYTE, LITHIUM ION SECONDARY BATTERY, AND METHOD FOR PRODUCING LITHIUM ION SECONDARY BATTERY - This invention relates to a matrix of a solid electrolyte having a microstructure in which a non-reactive polyalkylene glycol is held on a co-crosslinked product produced by chemically co-crosslinking a hyperbranched polymer with a crosslinkable ethylene oxide multicomponent copolymer, such that a lithium salt is dissolved in the matrix. A negative electrode active material layer is a layer obtained by dispersing a negative electrode active material and a conduction aid in a lithium-ion conducting solid electrolyte. A positive electrode active material layer is a layer obtained by dispersing a positive electrode active material and a conduction aid in a lithium-ion conducting solid electrolyte. | 12-13-2012 |
20120219582 | INTRANASAL SPRAY-TYPE TUBERCULOSIS VACCINE USING PARAMYXOVIRUS VECTOR - Disclosed is a intranasal spray-type | 08-30-2012 |
20120135422 | ANTI-GPCR ANTIBODY AND THE METHOD OF PRODUCING THE SAME - Disclosed is a discussion of a method for producing anti-mammalian GPCR antibody and of the antibody itself. Anti-mammalian GPCR antibody is produced through immunization involving exposure of fish to full-length or truncated mammalian GPCR, and anti-mammalian GPCR antibody that can be obtained by this method is also discussed. | 05-31-2012 |
20110319609 | BETA-1,3-GLUCAN MANUFACTURING METHOD - A method for manufacturing a linear-chain beta-1,3-glucan is disclosed that comprises polymerizing glucose-1-phosphate serving as a substrate by contacting the glucose-1-phosphate with a beta-1,3-glucan phosphorylase derived from a species in the genus | 12-29-2011 |
20110294928 | POLYCARBONATE RESIN COMPOSITION - Provided is a polycarbonate resin composition which has: a high degree of biomass (degree of vegetation); is excellent in environmental performance; has high fluidity and high impact resistance; is excellent in flame retardancy and heat resistance; and further provides a molded body excellent in molding appearance, by blending (B) a lignophenol at a specific ratio into (A) a polycarbonate resin or a resin mixture formed of the component (A) and (C) a polylactic acid and/or a copolymer containing a polylactic acid. | 12-01-2011 |
20110207864 | POLYORGANOSILOXANE COMPOSITION AND CURED PRODUCTION THEREOF - Disclosed are: a polyorganosiloxane composition which can be cured into a product having high strength and has little influence on the environment; and a cured product of the polyorganosiloxane composition. Specifically disclosed are: a polyorganosiloxane composition comprising (A) a polyorganosiloxane in which at least one end in the molecule is modified with a silanol, (B) a titanium alkoxide in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane, and (C) an α-hydroxycarbonyl compound or a hydroxycarboxylic acid ester in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane; and a cured product of the polyorganosiloxane composition. | 08-25-2011 |
20110006711 | APPARATUS FOR CARRYING OUT IMPROVED CONTROL OF ROTARY MACHINE - In an apparatus, a predicting unit uses, as an initial value of a controlled variable, at least one of a first measured value of the controlled variable and a second measured value of a physical variable expressed as a function of the controlled variable. The predicting unit predicts, based on the initial value of the controlled variable, a value of the controlled variable when a driving mode of a switching element of a power converter is set. A driving unit has an integral element and determines, based on an output of the integral element to which a deviation between the predicted value of the controlled variable and a command value of the controlled variable is inputted, an actual driving mode of the switching element to thereby drive the switching element in the determined driving mode. | 01-13-2011 |
20100221831 | LIVING BODY HOLDING METHOD, LIVING BODY TEST METHOD, LIVING BODY GROWING METHOD, LIVING BODY HOLDING SHEET, AND LIVING BODY PROCESSING DEVICE - A method of arranging a large number of living bodies, such as cells, embryos, or organisms rapidly, individually, and one by one, a holding sheet for the method, and a device for processing the living bodies. The method of holding living bodies includes using a sheet in which multiple through-holes with a size capable of holding one of the target living bodies, but not capable of holding two or more of the living bodies, are provided, to thereby arrange and hold the living bodies one by one in the multiple through-holes in the sheet together with a liquid. | 09-02-2010 |
20100025235 | METHOD FOR PRODUCTION OF RESPONSIVE GLASS MEMBRANE FOR ION ELECTRODE, RESPONSIVE GLASS MEMBRANE FOR ION ELECTRODE, AND ION ELECTRODE - Disclosed is a sensitive glass film for a pH electrode, which is not deteriorated in its glass strength or pH-measuring function, which is hardly stained, and from which any stain can be removed easily. Also disclosed is a pH electrode having the sensitive glass film. A microparticle comprising rutile-type or brookite-type titanium dioxide or a microparticle comprising amorphous titanium dioxide is adhered directly on the glass film surface of a sensitive glass film for a pH electrode. | 02-04-2010 |
20090324566 | T-Cell Receptor and Nucliec Acid Encoding the Receptor - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 12-31-2009 |
20090186364 | Method of Constructing Recombinant Proteoliposome for Diagnostic Use - [PROBLEMS] To provide a method for preparation of recombinant proteoliposomes suitable for diagnostic applications, a detection plate coated with the recombinant proteoliposomes, a detection kit and so on. | 07-23-2009 |
20090041859 | Wound Treatment Drugs for External Use - [Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. | 02-12-2009 |
20090035811 | Artificial scaffolding material for protein retention and use of the same - The present invention provides an artificial scaffolding material for retaining proteins suitable for placing contiguously one species or two or more species of proteins such as enzymes. To this end, the artificial scaffolding material for retaining proteins is provided with a cell and scaffolding proteins heterologous to the cell and placed on the surface layer side of the cell at an extent that allows aggregation properties to be conferred to the cell, and provided with a plurality of non-covalently binding protein-binding domains arranged in tandem. | 02-05-2009 |
20090035320 | Agents for Regulating Liver Regeneration/Repair - The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)). | 02-05-2009 |